Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: Inhibitory effects on receptormediated uPA activity in vitro and in vivo

Summary

Binding of urokinase plasminogen activator (uPA) to its cellular receptor, uPAR, potentiates plasminogen activation and localizes it to the cell surface. Focal plasminogen activation is involved in both normal and pathological tissue remodeling processes including cancer invasion. The interaction between uPA and uPAR therefore represents a potential target for anti-invasive cancer therapy. Inhibitors of the human uPA-uPAR interaction have no effect in the murine system. To enable in-vivo studies in murine cancer models we have now generated murine monoclonal antibodies (mAbs) against murine uPAR (muPAR) by immunizing uPAR-deficient mice with recombinant muPAR and screened for antibodies, which inhibit the muPA-muPAR interaction. Two of the twelve mAbs obtained, mR1 and mR2, interfered with the interaction between muPAR and the amino-terminal fragment of muPA (mATF) when analyzed by surface plasmon resonance. The epitope for mR1 is located on domain I of muPAR, while that of mR2 is on domains (II-III). In cell binding experiments using radiolabelled mATF, the maximal inhibition obtained with mR1 was 85% while that obtained with mR2 was 50%. The IC50 value for mR1 was 0.67 nM compared to 0.14 nM for mATF. In an assay based on modified anthrax toxins, requiring cell-bound muPA activity for its cytotoxity, a ~50% rescue of the cells could be obtained by addition of mR1. Importantly, in-vivo efficacy of mR1 was demonstrated by the ability of mR1 to rescue mice treated with a lethal dose of uPA-activatable anthrax toxins.

Keywords

Plasminogen activation - uPAR knock-out mice - mouse antimouse mAbs - inhibitors of uPA-uPAR interaction - anthrax toxin assay

• References

• 1 Dano K. et al. Cancer invasion and tissue remodeling-- cooperation of protease systems and cell types. APMIS 1999; 107: 120-127.
• 2 Dano K. et al. Plasminogen activation and cancer. Thromb Haemost 2005; 93: 676-681.
• 3 Freije JM. et al. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003; 532: 91-107.
• 4 Behrendt N. The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. Biol Chem 2004; 385: 103-136.
• 5 Ellis V. et al. Plasminogen activation by receptorbound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266: 12752-12758.
• 6 Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003; 9: 1499-1528.
• 7 Huai Q. et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006; 311: 656-659.
• 8 Llinas P. et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005; 24: 1655-1663.
• 9 Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943.
• 10 Pyke C. et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993; 53: 1911-1915.
• 11 Pyke C. et al. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994; 24: 131-138.
• 12 Usher PA. et al. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 2005; 113: 870-880.
• 13 Almasi CE. et al. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 2005; 48: 349-355.
• 14 Ganesh S. et al. Urokinase receptor and colorectal cancer survival. Lancet 1994; 344: 401-402.
• 15 Grondahl-Hansen J. et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1: 1079-1087.
• 16 Stephens RW. et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91: 869-874.
• 17 Kobayashi H. et al. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 1994; 57: 727-733.
• 18 Min HY. et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-2433.
• 19 Ploug M. et al. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001; 40: 12157-12168.
• 20 Romer J. et al. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 2004; 10: 2359-2376.
• 21 Solberg H. et al. Identification and characterization of the murine cell surface receptor for the urokinasetype plasminogen activator. Eur J Biochem 1992; 205: 451-458.
• 22 List K. et al. Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology. J Immunol Methods 1999; 222: 125-133.
• 23 Ronne E. et al. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett 1991; 288: 233-236.
• 24 Gardsvoll H. et al. Generation of high-affinity rabbit polyclonal antibodies to the murine urokinase receptor using DNA immunization. J Immunol Methods 2000; 234: 107-116.
• 25 Solberg H. et al. The murine receptor for urokinasetype plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem 2001; 49: 237-246.
• 26 Gardsvoll H. et al. Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical crosslinking. J Biol Chem 2006; 281: 19260-19272.
• 27 Bugge TH. et al. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 1995; 270: 16886-16894.
• 28 Shulman M. et al. A better cell line for making hybridomas secreting specific antibodies. Nature 1978; 276: 269-270.
• 29 de StGroth SF, Scheidegger D. Production of monoclonal antibodies: strategy and tactics. J Immunol Methods 1980; 35: 1-21.
• 30 Stoppelli MP. et al. Autocrine saturation of prourokinase receptors on human A431 cells. Cell 1986; 45: 675-684.
• 31 Liu S. et al. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001; 276: 17976-17984.
• 32 Kristensen P. et al. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol 1991; 115: 1763-1771.
• 33 Liu S. et al. Potent antitumor activity of a urokinase- activated engineered anthrax toxin. Proc Natl Acad Sci USA 2003; 100: 657-662.
• 34 Pass J. et al. Generation of antibodies to the urokinase receptor (uPAR) by DNA immunization of uPAR knockout mice: membrane-bound uPAR is not required for an antibody response. Scand J Immunol 2003; 58: 298-305.
• 35 Claesson MH. et al. Antibodies directed against monomorphic and evolutionary conserved self epitopes may be generated in 'knock-out' mice. Development of monoclonal antibodies directed against monomorphic MHC class I determinants. Scand J Immunol 1994; 40: 257-264.
• 36 Declerck PJ. et al. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995; 74: 1305-1309.
• 37 Declerck PJ. et al. Generation of monoclonal antibodies against autologous proteins in gene-inactivated mice. J Biol Chem 1995; 270: 8397-8400.
• 38 Nakamura N. et al. Generation of antibodies against prion protein by scrapie-infected cell immunization of PrP(0/0) mice. Hybrid Hybridomics 2003; 22: 263-266.
• 39 Meng G. et al. Murine TLR2 expression analysis and systemic antagonism by usage of specific monoclonal antibodies. Immunol Lett 2005; 98: 200-207.
• 40 Piironen T. et al. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 2004; 50: 2059-2068.
• 41 Cunningham O. et al. Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J 2003; 22: 5994-6003.
• 42 Rono B. et al. Antitumor efficacy of a urokinase activation- dependent anthrax toxin. Mol Cancer Ther 2006; 5: 89-96.
• 43 Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147-1157.
• 44 Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5: 292-302.
• 45 Kanai T. et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factorneutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998; 77: 933-936.
• 46 Katsumata M. et al. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med 1995; 1: 644-648.
• 47 Almholt K. et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2005; 113: 525-532.
• 48 Coussens LM. et al. MMP-9 supplied by bone marrow- derived cells contributes to skin carcinogenesis. Cell 2000; 103: 481-490.